Announcement on Changing the Purpose of Repurchased Shares and Cancellation

Securities Code: 002424 Securities Abbreviation: ST Bailin Announcement No.: 2026-041 Guizhou BaiLing Enterprise Group Pharmaceutical Co., Ltd. Announcement on Changing the Purpose of Repurchased Shares and Cancellation The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions. Guizhou BaiLing Enterprise Group Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 28th meeting of the Sixth Board of Directors on June 16, 2026, and reviewed and approved the "Proposal on Changing the Purpose of Repurchased Shares and Cancellation." Based on the actual situation and to protect the interests of the majority of investors, the Company intends to change the purpose of some of the repurchased shares from "for employee stock ownership plans or equity incentives" to "for cancellation and corresponding reduction of registered capital," meaning it plans to cancel 12,096,900 shares in the dedicated repurchase securities account and reduce the registered capital accordingly. This matter still needs to be submitted for review by the Company's shareholders' meeting. The relevant matters are hereby announced as follows: I. Repurchase Plan and Implementation The Company's Fifth Board of Directors held its 33rd meeting on January 9, 2023, and reviewed and approved the "Proposal on the Company's Share Repurchase Plan." It was agreed that the Company would use its own funds to repurchase a portion of its shares through centralized bidding for subsequent implementation of equity incentives or employee stock ownership plans. The repurchase amount shall not be less than RMB 100 million (inclusive) and not exceed RMB 200 million (inclusive). The estimated number of repurchased shares is between 7.22 million shares (inclusive) and 14.44 million shares